Change of Management

IP2IPO Group PLC
21 December 2005


For immediate release                                           21 December 2005


                                   IP2IPO GROUP PLC

               BOARD APPOINTMENT AND CHANGES TO MANAGEMENT STRUCTURE


IP2IPO Group plc ('IP2IPO') is pleased to announce the following changes to the
Board of the Company with effect from 1st January 2006:

(i) Alan Aubrey who joined the Board in January 2005 and became Managing
Director in September, will become Chief Executive Officer and will assume
overall management responsibility for the day-to-day operations of the Group,
management of the portfolio and relations with certain university partners;

(ii) David Norwood, formerly Chief Executive, will become Executive Chairman
with responsibility for Group strategy, relations with shareholders and certain
university partners. He will also be working closely with certain companies
within the IP2IPO portfolio with a focus on funding and exits;

(iii) Professor Graham Richards, formerly Non Executive Chairman, will become
Senior Non Executive Director;

(iv) Stephen Brooke will join the Board as Director of Business Development.
Stephen has worked for IP2IPO since September 2003 during which time he has been
responsible for IP2IPO's business development activity and worked with a number
of IP2IPO's university partners and spinout companies.  Stephen joined IP2IPO
from Columbia University Science and Technology Ventures, the technology
transfer office of Columbia University in New York, and has spent his career in
venture capital, investing in and building companies across numerous industries
in South Africa, the UK and US.

Following these changes, the Board will be comprised as follows:-

David Norwood - Executive Chairman
Alan Aubrey - Chief Executive Officer
Professor Graham Richards - Senior Non Executive Director
Roger Brooke - Non Executive Director
Bruce Smith - Non Executive Director
Bruce Campbell - Chief Scientific Officer
Alison Fielding - Director of Technology Transfer
Stephen Brooke - Director of Business Development

Alan Aubrey, Chief Executive of IP2IPO, commented: 'We are delighted to announce
Stephen Brooke's appointment to the Board. He has made a major contribution to
the strategy and growth of the Company to date and we are confident that the
changes in executive management responsibility announced today will position the
Company well for the next stage in its growth.'

The following information is provided in accordance with paragraph 17 and
schedule 2 paragraph g of the AIM Rules:

Stephen Henry Ralph Brooke, aged 32: (a) has held the following directorships
during the past 5 years: Amaethon Limited, Pharminox Limited, Bioniqs Limited
and Oxford Nanolabs Limited; (b) has no unspent convictions in relation to
indictable offences; (c) has not had any bankruptcy order against him or entered
into any voluntary arrangement; (d) has not been a director of any company which
has been placed into receivership, compulsory liquidation, creditors' voluntary
liquidation, administration or which has entered into any company voluntary
arrangement or any composition or arrangement with its creditors generally or
any class of its creditors, at the time of or within 12 months preceding such
event; (e) has not been a partner of any partnership which has been put into
compulsory liquidation, administration or entered into partnership voluntary
arrangements, at the time of or within 12 months preceding such event; (f) has
not had a receivership of any asset or of a partnership where he was a partner,
at the time of or within 12 months preceding such event or (g) has not been
publicly criticised by any statutory or regulatory authorities (including
recognised professional bodies) or ever been disqualified by a court from acting
as a director of a company or from acting in the management of the affairs of
any company.


For more information please contact:

IP2IPO                                                             020 7489 5200
Alan Aubrey, Chief Executive Officer

Buchanan Communications                                            020 7466 5000
Tim Anderson, Mary-Jane Johnson


Notes for editors

IP2IPO is an intellectual property (IP) company that specialises in
commercialising university technology. The Company was founded in 2001 and
listed on the AIM Market of the London Stock Exchange plc in October 2003.
IP2IPO's first partnership was with the University of Oxford. In return for an
investment of £20 million, IP2IPO has acquired 50 per cent of the University of
Oxford's equity in spin-out companies and technology licenses based on
intellectual property created at the Chemistry Department until 2015. In
November 2003, IP2IPO created a £5 million seed capital fund for investing in
spin-out companies across the University of Oxford, not just those originating
within the Chemistry Department.

In March 2002, IP2IPO entered into a second long-term partnership with the
University of Southampton. Under the terms of this partnership, IP2IPO is
committed to working with the University of Southampton in the identification
and facilitation of spin-out companies from across the University of Southampton
and to investing £5 million in early-stage University of Southampton spin-out
companies over a four year period in return for equity stakes in those
companies. In addition, IP2IPO also received a 20 per cent stake in Southampton
Asset Management Limited, a company that has been formed to hold the
University's equity stakes in its spin-out companies. The partnership has a term
of at least 25 years.

IP2IPO entered into its third long-term partnership in May 2003 with King's
College London. IP2IPO works with King's College London to help identify and
progress commercialisation opportunities as well as invest £5 million in seed
capital in spin-out companies from King's College London over a five year period
in return for equity stakes in those companies. In addition, IP2IPO receives 20
per cent of King's College London's equity in spin-out companies and technology
licenses. The partnership has a term of 25 years.

In October 2003, IP2IPO announced a fourth partnership with the Centre for Novel
Agricultural Products ('CNAP'), based at the University of York. CNAP is a
flagship research centre that specialises in plant and microbial gene discovery.
Under the terms of the partnership a new company, Amaethon Limited, has been
created which has the right to commercialise CNAP's IP for 25 years. IP2IPO has
invested £1.15m in Amaethon Limited in return for a 40% equity stake in Amaethon
Limited (the remaining equity being owned by the University of York) and will
also invest in the spin-out companies based on CNAP's IP which Amaethon Limited
creates.

In June 2004, IP2IPO acquired Top Technology Ventures Limited, an investment
adviser to early stage technology funds. This combines IP2IPO's expertise in the
creation of new ventures based on world leading university IP with Top
Technology's focus on making early stage venture capital investments.

In January 2005, IP2IPO acquired Techtran, a company set up in 2002 to
commercialise university intellectual property under a long-term technology
commercialisation contract with the University of Leeds. Under the terms of the
contract Techtran receives a significant (30%) interest in spin-out companies
created and technology licences negotiated, in return for the provision of
technology transfer services to the University.

In May 2005, IP2IPO announced the launch of LifeUK, a new subsidiary company.
LifeUK, which has since been renamed Modern Biosciences, will in-license life
science intellectual property created by medical researchers at universities
with which IP2IPO already has partnerships, other universities in the UK and
similar academic and charitable research institutions. Modern Biosciences'
objective is to further develop the intellectual property which it in-licenses
with a view to creating substantial value either by subsequently licensing these
development programmes to the pharmaceutical industry or via the creation of new
ventures.

In December 2005, IP2IPO entered into its sixth long-term partnership with the
University of Bristol. IP2IPO will work with the University of Bristol to help
identify and progress commercialisation opportunities as well as invest an
initial £5 million in seed capital in spin-out companies from the University of
Bristol over a five year period in return for equity stakes in those companies.
In addition, IP2IPO will receive 13.3% per cent of in spin-out companies at the
time that the company is established prior to investment. The partnership has a
term of 25 years.

To date, 5 spin-out companies from the IP2IPO portfolio have listed on the AIM
Market of the London Stock Exchange plc: Offshore Hydrocarbon Mapping plc,
Synairgen plc, VASTox plc, Proximagen Neuroscience plc and GETECH Group plc.
There has been one trade sale: Toumaz Technology Limited was sold to Nanoscience
Inc.


                      This information is provided by RNS
            The company news service from the London Stock Exchange